Cocrystal Pharma Q1 net loss $2.3M, cash $6.9M; CDI-988 shows broad norovirus activity, human challenge planned

Cocrystal Pharma, Inc.

2025-Q1 EPS reported -$0.23

Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
R&D expenses decreased to $1.4M from $3.0M; G&A down to $1.0M from $1.2M.
Unrestricted cash $6.9M at March 31, 2025 vs $9.9M at Dec 31, 2024; working capital $6.9M.
CDI-988 showed superior broad-spectrum antiviral activity against norovirus GII.17 strains; expects to report topline Phase 1 high-dose results in Q2 2025.
Plan to initiate a U.S. human challenge study for CDI-988 as norovirus treatment and prophylaxis in coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.